. -miR-17p3,4 (10nM) . (C) Dose-response experiment with electroporation of increasing amounts of CSFV wt or CSFV-m17p3,4 RNA followed by cell-based E2 reactivity ELISA. (D) Establishment of SK-6 cells expressing miR-17 or miR-17p3,4. SK-6 cells were transduced with lentiviruses expressing the indicated miRNA and GFP. Stably expressing cells were sorted by FACS for GFP expression. (E) Cell lines from (D) were subjected to psiCHECK-2 reporter assay for miR-17p3,4. (F) miR-17 levels were quantified by qRT-PCR in MDBK (bovine), BT (bovine), PK-15 (porcine) and Huh-7.5 (human) cells. Expression levels were normalized for the relatively stably expressed miR-21, or for total RNA. (G) BVDV driven translation was measured from bi-cistronic BVDVm17p7,8 reporters +/-mutations of the terminal stem-loop and after trans-complementation with miRNA mimics as indicated (10nM). Location of mutations is indicated in the schematic to the right. Mean +/-SEM (A) or +/-SD (E and G) is shown. Schematics of reporters as in Figure S5 . shown as a function of biologic complexity (BC). The number (n) of read clusters with a minimum of the given BC is shown below. (C) Log 2 -fold change in AGO-CLIP binding between BVDV infected and uninfected cells for all 3' UTR clusters broken down by seed type (as defined by (Bartel, 2009) ) of miR-17 or any of the top 50 miRNAs ("All"). Boxplot shows mean and 25 th to 75 th percentile with min/max whiskers. *: p<0.05 by one-sided t-test. ns: non-significant. (D-F) Cumulative density functions (CDF) of the log 2 -fold change in AGO-CLIP binding between BVDVcp infected and mock cells for all 5'UTR (D), coding sequence (CDS) (E), and intron (F) clusters containing indicated 8-mer seeds by family, from quadruplicate experiments. "Top 10" refers to the ten most abundant CLIP-derived Ago-bound miRNAs in MDBK cells. Two-sided K-S test p-values of difference to "All" are shown. (G) Log 2 -fold change in CLIP binding as in (C) but for tinyLNA-17 treated cells compared to mock. *: p<0.05 and ***:p<0.0001 by one-sided t-test. ns: non-significant. (H-J) CDF plots as in (D-F) but measuring expression of targets with indicated 8mer seeds in the 3' UTR via mRNA-seq, from duplicate experiments. BVDVcp infection was compared to mock (H), miR-17p3,4 transfection (10nM) was compared to mock (I), or miR-17p3,4 trans-complemented (10nM) BVDVcp-m17p3,4 infected was compared to miR-17p3,4 transcomplemented mock (J). Targets with more than one miRNA binding site were collapsed such that no gene is represented more than once per category. (K-L) CDF plots as in (H-J), but for CSFV vEy-37-infected IFN-γ-polarized porcine monocyte-derived macrophages 8hrs (K) and 20hrs (L) post infection, from triplicate experiments. Figure 7 . Provided as a 2-sheet Excel file. The abundance of AGO-loaded miRNAs in MDBK cells is given by seed family (sheet 1). In addition, fraction of total for individual miRNAs is given for four replicates each of MDBK (mock) and MDBK (BVDV infected) (sheet 2). For clusters in genic regions with a minimum total biologic complexity (BC) of 4, the peak height (PH) and BC for mock, BVDVcp and total are given. The normalized CLIP PH was calculated by addition of a pseudocount of 1 per condition and dividing by the total library size. The log 2 fold change in AGO-CLIP binding was calculated directly from the normalized PH. Gene expression values corresponding to CLIP-defined clusters were calculated from mRNA-seq data in edgeR and logCPM (counts per million), log 2 fold change and adjusted p-values (FDR) are given. Additional data include the genic region (CDS, UTR, intron) covered by the largest fraction of each cluster, the cluster sequence, and the presence or absence of seed sites (6mer, 7merA1, 7merM8, 8mer) of the 50 most abundant miRNAs in MDBK cells (Table S3) . Sheet 2. Summarized AGO-CLIP analysis for tinyLNA-17 and mock treated MDBK cells. The table summarizes AGO-CLIP clusters from analysis of tinyLNA-17 vs. mock treated MDBK cells (four replicates each). For clusters in genic regions with a minimum total biologic complexity (BC) of 4, the peak height (PH) and BC for mock, tinyLNA-17 and total are given. The normalized CLIP PH was calculated by addition of a pseudocount of 1 per condition and dividing by the total library size. The log 2 fold change in AGO-CLIP binding was calculated directly from the normalized PH. Additional data include the cluster fraction mapping to each genic region (CDS, UTR, intron), the cluster sequence, and the presence or absence of seed sites (6mer, 7merA1, 7merM8, 8mer) of the 50 most abundant miRNAs in MDBK cells (Table S3) . Sheet 3. Summarized mRNA expression analysis for BVDV and mock infected MDBK cells. The table summarizes RNA expression levels measured by mRNA-seq for mock, BVDVcp or BVDVncp infected MDBK cells, and for miR-17p3,4 transfected MDBK cells infected or not with BVDVcp-m17p3,4 or BVDVncp-m17p3,4. Gene expression values were calculated using general linear models in edgeR and logCPM (counts per million), log 2 fold change and adjusted p-values (FDR) are given for pairwise comparisons. Table S5 . Lists of genes regulated by pestiviral miR-17 sponge effect. Related to Figure 7 . Provided as a 3-sheet Excel file. Three lists of genes and associated fold change values in CLIP (for BVDV) and mRNA-seq (BVDV and CSFV) are given: List 1 (sheet 1) contains MDBK mRNAs with a CLIP-supported miR-17 8mer in their 3' UTR, significantly upregulated 24hrs post BVDV infection. List 2 (sheet 2) contains MDBK mRNAs with reduced AGO binding at 3' UTR miR-17 6-8mer sites, significantly upregulated 24hrs post BVDV infection. List 3 (sheet 3) contains unstimulated porcine macrophage mRNAs with a miR-17 8mer in the 3' UTR, significantly upregulated 20hrs post CSFV infection. Table S6 . Sequence contexts and oligonucleotides. Related to Experimental Procedures. Provided as a 6-sheet Excel file. Sheet 1. Differences between virus sequences used here and published sequences. Sheet 2. Sequence context of modifications to BVDV, CSFV and reporter plasmids. Sheet 3. Sequences of miRNA mimics and LNAs. Sheet 4. Primers and probes for qPCR assays. Sheet 5. Primers for sequencing the BVDV ORF. Sheet 6. Primers for CLIP multiplexing and target-CLIP. Table S7 . AGO-CLIP metadata. Related to Figure 1 -4, 7 and Experimental Procedures. Provided as an Excel file. Alignment statistics for AGO-CLIP data presented throughout the manuscript. Total sequence reads were filtered for quality, collapsed on identical sequence and the 3' adapter was trimmed before splitting based on index while the unique barcode introduced at the RNA stage was retained in the sequence name. Then, each separated sample was aligned to host and viral reference genomes as appropriate. The percentage of uniquely mapped reads of total is given.
SUPPLEMENTAL TABLES

SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Culture of Cell lines and primary cells
Huh-7, -7.S10.3 (A gift from Suzanne Emerson, NIAID, NIH), -7.5 (Blight et al., 2002) and -7.5ΔDrosha , HEK293, HeLa and A549 cells were maintained in DMEM supplemented with 10% FBS and non-essential amino acids, BHK-J cells in AEM with 10% FBS and non-essential amino acids, STAT1 -/-fibroblasts (Dupuis et al., 2003) in RPMI with 10% FBS, MDBK and BT in DMEM with 10% horse serum, non-essential amino acids and 0.1mM sodium pyruvate, PK-15 in DMEM with 5% horse serum, non-essential amino acids and 0.1mM sodium pyruvate, and SK-6 (Kasza et al., 1972) in MEM with 7% horse serum. Porcine monocyte-derived macrophages were differentiated from peripheral blood mononuclear cells (PBMC) from specific pathogen-free blood donor pigs of the IVI, Switzerland (experiment licenses BE26/11 and BE88/14) as described previously (Auray et al., 2010; Garcia-Nicolas et al., 2014) . Briefly, PBMC were isolated on a FICOLL-PAQUE Plus gradient (GE Healthcare) and the monocytes purified by positive selection on LS columns using human CD14-coupled magnetic beads and the Magnetic Activated Cell Sorting system (MACS, Miltenyi Biotec). For differentiation to macrophages, the sorted monocytes (purity > 95%) were seeded in 12-well plates at 10 6 cells/well in 2ml DMEM and 10% heat-inactivated porcine serum (Sigma). The cells were then cultured for 3 days at 39°C with 5% CO 2 . After 3 days, medium was replaced and cells were polarized for 24h in medium with IFN-γ (10 ng/ml, R&D Systems) or left untreated (unpolarized). 
Infection conditions for CLIP
CLIP assays
Standard AGO-CLIP was done as described (Moore et al., 2014) . To enable cost-effective multiplexing as well as compatibility with sequencing on MiSeq machines, we adapted the 2 nd PCR step of the protocol to add sequencing adapters and 5' indices using the twenty forward primers and the reverse primer MSFP3 listed in Table S6 . This strategy uses the DP5 and DP3 sequences of the 1st PCR product as priming sites to add 5' indices and 3' adapters for a short (6-16 cycles) 2nd PCR step. CLEAR-CLIP is based on standard AGO-CLIP with modifications to enrich for miRNA-target chimeras (Moore et al., 2015) . Briefly, the following procedures replace the post-immunoprecipitation steps of standard AGO-CLIP: (i) 5'-end phosphorylation using PNK (3' phosphatase minus), (ii) Over-night chimera ligation using T4 RNA ligase 1, (iii) Alkaline phosphatase treatment to remove 3' phosphate groups, (iv) 3'-linker ligation using truncated T4 RNA ligase 2 and preadenylated linker (using a pre-adenylated linker and omitting the enzyme in step ii allows negative controls to distinguish cellular vs. on-bead ligation events), and (v) Radio labeling using T4 PNK and [γ-32 P]-ATP. Here, the ligase-free controls used to establish the method (Moore et al., 2015) were not needed, and the 3' linker ligation was therefore done with T4 RNA ligase 1 and a radioactively labeled phosphorylated RNA linker according to the standard AGO-CLIP protocol (Moore et al., 2014) , and not using truncated T4 RNA ligase 2 and a pre-adenylated linker. Accordingly, the subsequent PNK treatment was done with non-radioactive ATP. For target-CLIP, step (i) of the CLEAR-CLIP procedure was done with [γ-32 P]-ATP to radiolabel the RNA, followed by step (ii). Since a 3' linker is not needed for target-CLIP, steps (iii)-(v) were omitted. For target-CLIP on the HCV 5' end, treatment with RNA 5´ Polyphosphatase (Epicentre) was done prior to step (i) to first reduce the HCV RNA 5' tri-phosphate group to a mono-phosphate allowing PNK reaction. The DP3 and MSFP3 reverse primers used for cDNA synthesis, 1 st and 2 nd PCRs were replaced with target specific primers (Table S6) .
Construction of virus, reporter and lentivirus plasmids
HCVm15/122 and HCVm122/15 were derived from wt and m15 variants of J6/JFH1-clone2 or Jc1FLAG(p7-nsGluc2A) by swapping single miRNA binding sites (Table S6) . Mutants of the BVDV cp and ncp NADL strain (Mendez et al., 1998) and the CSFV vA187-1 strain (CSFV wt) (Ruggli et al., 1996) were made using standard PCR, cloning and Gibson assembly methods. The introduced modifications are listed in Table S6 . The BVDV pol(-) mutant was previously described (Agapov et al., 2004) . Due to toxicity of pestivirus sequences to E. coli, plasmids were transformed into Sure 2 supercompetent cells (Agilent Technologies), and small-to-medium sized colonies were picked and grown in standard broth over night. Smallscale plasmids were prepared using Qiaprep spin plasmid miniprep (Qiagen) and check-digested. 200µL of the starter culture were re-inoculated into 250-500mL terrific broth and grown over night. Large-scale plasmids were prepared with QIAfilter maxiprep (Qiagen) using triple amounts of buffers P1-P3 and additional funnels and filter papers to remove bacterial debris. The complete pestivirus plasmid component was sequenced (Macrogen). Bi-cistronic BVDV Fluc translation reporters were made using standard PCR and cloning techniques and carried a capped Rluc reporter, a NotI site, the entire BVDV IRES and the first 27 nts of the BVDV ORF fused to Fluc (with an AgeI site introduced immediately upstream of Fluc). The entire BVDV 3'UTR was inserted seamlessly downstream of Fluc. Modifications to the BVDV 3' UTR are listed in Table S6 . Appropriate sequences were introduced between the XhoI and NotI sites in the Rluc 3' UTR of the psiCHECK-2 reporter. The inserted sequences are listed in Table S6 . For construction of lentiviruses, a genomic DNA fragment encompassing porcine miR-17 (Table S6 ) was amplified by PCR with Phusion Hot Start II High-Fidelity DNA polymerase (Thermo Scientific) using DNA from the porcine PEDSV.15 cell line (Seebach et al., 2001 ). The fragment was cloned into pSUPER (Oligoengine, Seattle, WA, USA) immediately downstream of the histone 1 polymerase III-dependent (H1) promoter using BglII and HindIII. The H1-shRNA cassettes were transferred from pSUPER using EcoRI and ClaI and cloned into pLV-THM (kindly provided by Didier Trono, Ecole Polytechnique Fédérale, Lausanne, Switzerland), giving rise to pLV-THM-ssc-miR-17 and pLV-THM-ssc-miR-17p3p4, respectively. These vectors express eGFP under the EF-1 promoter, and the miRNA under the H1 promoter.
RNA transcription, electroporation and transfection
To produce viral RNA for electroporation of (+)RNA viruses, DNA was linearized according to the guidelines for the specific infectious clone and purified on Wizard SV Gel and PCR Clean-Up System (Promega). Capped RNA was produced using mMESSAGE mMACHINE T7 Transcription Kit (Ambion) and non-capped RNA was produced using T7 RiboMAX Express Large Scale RNA Production System (Promega) or MEGAscript T7 (Ambion). The RNA was DNAse treated for 30 min on ice, purified using RNeasy mini kit (Qiagen) and quantified and visualized using Nanodrop and gel electrophoresis.
A BTX ElectroSquare Porator ECM 830 was used for electroporations as described . Typically, 5 µg RNA was added to 400 µL suspension of 6x10 6 Huh-7.5 (5 pulses of 100µs, 860V over 1.1 sec), 8x10 6 MDBK (10 pulses of 100µs, 900V over 1.1 sec) or 6x10 6 BHK cells (5 pulses of 100µs, 960V over 1.1 sec). SK-6 cells were electroporated with 1 µg viral RNA as described (Mayer et al., 2004; Ruggli et al., 1996) . CSFV RNA transfections of SK-6 and lentiviraltransduced SK-6 cells were performed with 150ng viral RNA per well using Lipofectamine 2000 (Life Technologies). Trans-complementation with mutant miRNA mimics (GE Dharmacon) or tinyLNAs (Exiqon) (sequences given in Table S6 ) was for BVDV experiments done 24hrs post electroporation, and for CSFV experiments also before or together with CSFV electroporation. For assays with infection, trans-complementation was done 24hrs prior to infection, and in the case of tinyLNAs also immediately following infection. Briefly, Lipofectamine RNAi/MAX (Life Technologies) was mixed with small RNAs in Opti-MEM and incubated for 5 min. The solution was then added on top of the monolayer growing in fresh growth media, except for experiments with tiny-LNA-let-7, where cells were cultivated over night in pure Opti-MEM.
RNA purification and titration RNA was purified on RNeasy mini kit (Qiagen) or Direct-zol RNA MiniPrep (Zymo Research) and concentrations were measured on Nanodrop. Quantification of viral RNA was done on a LightCycler 480 (Roche) using (i) TaqMan Fast Virus 1-Step Master Mix (Applied Bioscience) in a one-step qRT-PCR at 50°C for 30 min, 95°C for 5 min followed by 40 cycles of 95°C for 15 sec, 56°C for 30 sec and 60°C for 45 sec, or (ii) a two-step procedure using SuperScript III (Life Technologies) for cDNA synthesis followed by a qPCR using SYBR Green PCR Master Mix (Applied Biosystems) at 95°C for 10 min followed by 40 cycles of 95°C for 15 sec, 55°C for 30 sec and 60°C for 30 sec. Standard curves were generated from in vitro transcribed RNA from infectious clones, quantified (Nanodrop) and diluted to cover the range of 5x10 8 -5x10 1 GE/µL. Primers and probes for individual viruses are given in Table S6 . miRNAs were quantified using miScript II RT kit (Qiagen) and qPCR using SYBR Green PCR Master Mix (Applied Biosystems) and forward primers identical to the miRNA sequence with cycle parameters as above. Standard curves were generated by diluting miRIDIAN miRNA mimic (GE Dharmacon) to the range of 1x10 8 -1x10 1 copies/µL.
Viral infectivity titration and monitoring of infection
For PFU assays, cells were plated in 6-well plates and one day later infected with 10-fold dilution series for 1hr rocking before overlay with a 1:1 mix of 2x growth medium and Avicel RC-581 (FMC Biopolymer) or agar. Plates were then left untouched until fixation with 3.7% formaldehyde and staining using crystal violet. BVDV was titrated on 4x10 5 MDBK cells per well for 48-54hrs using 2.4% Avicel. YFV-17D-GFP was titrated on 4x10 5 Huh-7.5 cells per well for 120hrs using 2.4% Avicel. SINV was titrated on 4x10 5 Huh-7.5 cells per well for 48-54hrs using 4% Avicel. CHIKV was titrated on 4x10 5 BHK-J cells per well for 48hrs using 2.4% Avicel. Polio was titrated on 8x10 5 HeLa cells per well for 42hrs using 1.8% Oxoid agar. CVB was titrated on 8x10 5 HeLa cells per well for 72hrs using 1.2% regular agar. IAV was titrated on MDCK cells using 2.4% Avicel. HCV was titrated by the TCID 50 (Lindenbach et al., 2005) or FFU (Gottwein et al., 2009 ) method. BVDVncp was titrated by the TCID 50 method: 5x10 3 MDBK cells were plated per well of a 96-well plate one day before inoculation with 10-fold dilution series of the samples for 48hrs. The monolayer was fixed using 3.7% formaldehyde, permeabilized with 0.25% Triton X-100 in PBS and blocked using PBS with 1% horse serum and 0.25% Triton X-100. Cells were then bound by anti-BVDV polyclonal antibody B224 (1:250 in PBS-0.25% Triton X-100, kindly provided by Kenny Brock) and anti-bovine IgG peroxidase conjugate antibody (Sigma, A-5295) before staining with DAB substrate (DAKO). CSFV was titrated by the TCID 50 method on SK-6 or SK6-LV-miR-17p3,4 cells (see below) and immunoperoxidase-stained using the monoclonal antibody HC/TC26 (Greiser-Wilke et al., 1990) . HAV was titrated by the TCID 50 or FFU method on Huh-7.5-RFP-nls-MAVS cells (Jones et al., 2010) with the HAV cleavage site in MAVS (Yang et al., 2007) added to the reporter construct (HAV Dependent Fluorescent Reporter cells, HADFR) (Tim Sheahan, unpublished).
To titrate pestivirus mutants depending on mutated miRNAs, cells were reverse transfected upon plating. Briefly, Lipofectamine RNAi/MAX was mixed with miRNA mimic (final concentration corresponding to that of the assay being titrated), incubated for 5 min and then added to 5x10 5 MDBK cells per well before plating in a 6-well plate, or 6x10 3 cells per well of a 96-well plate. For experiments following spread of HCV infection, cells were split onto 8-well chamberslides and stained as described (Gottwein et al., 2007) . Replication of Gaussia luciferase expressing HCV genomes was monitored as described . Infection with other viruses was monitored by titration or GFP signal. The specific infectivity of CSFV RNA transcripts was determined in an infectious center assay (Mayer et al., 2004) . For focus size assays, viral RNA-electroporated SK-6 cells were covered with semi-solid agarose medium composed of DMEM with 5% porcine serum, 1% low melting point agarose (Gibco, Life Technologies) and 0.2 % LE agarose (Promega, Madison, USA), and incubated for 48h at 37°C. For immunoperoxidase staining of CSFV E2 with HC/TC26 antibody, the agarose overlay was removed and the cells were fixed for 1h at 80°C. The cell-based CSFV E2 reactivity ELISA was performed similarly by omitting the semi-solid agarose overlay and by using a soluble HRP substrate (OPD, Sigma) for the quantification of the E2-specific signal by optical density.
Sequencing of viral RNA from supernatant Viral RNA from supernatants was purified using High pure viral nucleic acid kit (Roche), and cDNA was synthesized using SuperScriptIII and random nonamers in a gradient from 50°C to 55°C over 60 min, followed by treatment with RNAse H and T1 for 20 min at 37°C. The 1 st and 2 nd PCR were using Accuprime Pfx supermix (Life Technologies) with cycling parameters 95°C for 5 min followed by 35 cycles of 95°C for 20 sec, 55°C for 10 sec and 70°C for 1-3 min. Primers for this procedure are listed in Table S6 .
Luciferase reporter assays psiCHECK-2 miRNA reporter assays were done as described transfecting 1-10ng DNA into 5x10 4 , 1x10 4 or 2x10
